PSC
ABBV icon

Portman Square Capital’s AbbVie ABBV Stock Holding History

Portman Square Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-223,800
Closed -$46.9M – 182
2025
Q1 		$46.9M Buy
223,800
+174,200
+351% +$33.9M 1.25% 18
2024
Q4 		$8.81M Sell
49,600
-5,900
-11% -$1.08M 0.32% 79
2024
Q3 		$11M Hold
55,500
– – 0.41% 76
2024
Q2 		$9.52M Sell
55,500
-69,600
-56% -$11.5M 0.33% 98
2024
Q1 		$22.8M Sell
125,100
-40,300
-24% -$6.95M 0.63% 48
2023
Q4 		$25.6M Buy
165,400
+59,400
+56% +$8.66M 0.59% 43
2023
Q3 		$15.8M Hold
106,000
– – 0.39% 65
2023
Q2 		$14.3M Buy
106,000
+79,900
+306% +$11.7M 0.41% 66
2023
Q1 		$4.16M Buy
+26,100
New +$3.99M 0.19% 103

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Portman Square Capital's ABBV Position: Q3 2024 in Review

Portman Square Capital sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 1,828 shares — an estimated $341K sold.

Portman Square Capital first reported a position in ABBV in Q1 2023 and held it in 6 quarters. The position peaked at $2.25M in Q2 2023. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • Portman Square Capital reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
  • Portman Square Capital sold 1,828 AbbVie shares in Q3 2024, an estimated $341K.
  • Portman Square Capital first reported a position in AbbVie in Q1 2023 and held it in 6 quarters.
  • Portman Square Capital's AbbVie position peaked at $2.25M in Q2 2023.
  • 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Portman Square Capital's 13F filing for Q3 2024, filed 16 Oct 2024.